Andreescu J, Ocanto A, Couñago F. Prognostic significance of nutritional and inflammatory markers in colorectal cancer. World J Clin Oncol 2025; 16(6): 104958 [DOI: 10.5306/wjco.v16.i6.104958]
Corresponding Author of This Article
Abrahams Ocanto, MD, Department of Radiation Oncology, Genesis Care-San Francisco de Asís University Hospital, Calle Joaquín Costa, 28, Madrid 28002, Spain. abrahams.ocanto@genesiscare.es
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jun 24, 2025; 16(6): 104958 Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.104958
Prognostic significance of nutritional and inflammatory markers in colorectal cancer
Jon Andreescu, Abrahams Ocanto, Felipe Couñago
Jon Andreescu, Department of Radiation Oncology, San Juan de Dios University Hospital, Genesis Care, Córdoba 14012, Spain
Abrahams Ocanto, Felipe Couñago, Department of Radiation Oncology, Genesis Care-San Francisco de Asís University Hospital, Madrid 28002, Spain
Abrahams Ocanto, Program in Medicine and Surgery, Doctoral School, Universidad Autónoma de Madrid, Madrid 28049, Spain
Author contributions: Andreescu J, Ocanto A and Couñago F contributed to this paper; Andreescu J, Ocanto A and Couñago F designed the overall concept and outline of the manuscript; Andreescu J contributed to the discussion and design of the manuscript; Andreescu J, Ocanto A and Couñago F contributed to the writing, and editing the manuscript and review of literature.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Abrahams Ocanto, MD, Department of Radiation Oncology, Genesis Care-San Francisco de Asís University Hospital, Calle Joaquín Costa, 28, Madrid 28002, Spain. abrahams.ocanto@genesiscare.es
Received: January 7, 2025 Revised: February 23, 2025 Accepted: March 5, 2025 Published online: June 24, 2025 Processing time: 164 Days and 15.1 Hours
Abstract
Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related mortality worldwide, responsible for approximately 900000 deaths annually. Inflammation and malnutrition significantly influence patients' responses to treatment. Markers such as serum albumin concentration, the prognostic nutritional index, nutritional risk index (NRI), geriatric NRI, and the systemic immune-inflammation index enable the early identification of high-risk patients, facilitating timely interventions that can improve survival and reduce morbidity. A comprehensive understanding and application of these markers allow for better risk stratification in CRC patients, optimizing their management and outcomes.
Core Tip: Colorectal cancer (CRC) patients are significantly impacted by weight loss, cancer-associated sarcopenia, and malnutrition, all of which affect prognosis and treatment adherence. There is a growing body of evidence highlighting the prognostic significance of nutritional and inflammatory markers in CRC. Integrating these markers into patient screening is crucial for identifying high-risk patients and implementing preemptive measures to improve outcomes.
